Related Experiment Video
Updated: Jun 12, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Bortezomib for refractory antibody-mediated cardiac allograft rejection
Peter M Eckman1, Marit Thorsgard, David Maurer
1Department of Medicine, University of Minnesota, USA.
Clinical Transplants
|June 8, 2010
Abstract:
This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.